Open AccessA Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung
Author(s) -
Xiaojing Jia,
Qianru He,
Xiaodan Xing,
Yanming Yang,
Yan Ma
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s347200
Subject(s) - anaplastic lymphoma kinase , crizotinib , fusion gene , immunohistochemistry , adenocarcinoma , lung cancer , cancer research , fluorescence in situ hybridization , medicine , stage (stratigraphy) , biology , pathology , gene , cancer , genetics , paleontology , malignant pleural effusion , chromosome
Anaplastic lymphoma kinase ( ALK ) gene rearrangement is an essential driver mutation identified in approximately 5% of non-small cell lung cancers (NSCLCs). The results of clinical trials have demonstrated the impressive efficacy of ALK tyrosine kinase inhibitors (ALK-TKIs). Besides the classic EML4-ALK fusions, a growing list of gene fusion partners for ALK in NSCLC have been identified with heterogeneous clinical responses to ALK-TKIs. However, a LOC101927967-ALK fusion has not been reported in NSCLC. Herein, a novel LOC101927967 downstream intergenic region ALK fusion in an early-stage patient with lung adenocarcinoma was first identified by next-generation sequencing (NGS) and verified by immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH), which might provide a treatment option for postoperative recurrence.